Project Grant R01AI187259
- This $838,320 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant will fund research to investigate fungal pathogenicity determinants and their relationship to emerging cancer therapies that can lead to increased risk of invasive fungal infections. Specifically, the research aims to understand the mechanism by which inhibition of the Bruton's...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,193,457 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMASS Medical) to produce, validate, and provide relevant fungal antigens to the scientific community. The funding will support the manufacturing of crude antigenic preparations from various fungal pathogens, as well as the recombinant production and testing of 36...
- This Project Grant award of $104,262, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to explore the relationship between genetic variants, transcriptional responses, and tuberculosis (TB) infection outcomes in macrophages derived from genetically diverse mice. The project aims to understand the basis for variability in TB infection outcomes, which may help identify ways to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $101,982 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Massachusetts Medical School (UMMS) to conduct research on the "Temporal Regulation of mRNA Biogenesis in Immune Responses." This 21-month project, running from May 2025 to February 2027, seeks to uncover mechanistic insights into the regulation and impact of stimulus-induced immune mRNA...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This federal Project Grant award of $586,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research at the University of Massachusetts Medical School (UMass Medical) to investigate the generation and regulation of TFH13 cells that drive pathogenic IgE in allergic conditions. The overarching goal is to elucidate the pathways leading to TFH13 cell differentiation, which play a critical...
- This $117,883 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) on September 1, 2025. The grant will support research at the University of California, Berkeley to investigate the role of Bruton's tyrosine kinase (BTK) in maintaining B-cell anergy, which is critical for preventing autoimmunity. The research aims to elucidate how BTK's unique ability to dimerize on...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $750,815 to the University of Maryland, Baltimore to conduct research on therapeutic targeting of the host hypoxia-response pathway to treat mucormycosis, a deadly invasive fungal infection. The research aims to develop alternative strategies to treat and prevent mucormycosis, which has limited treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $147,486 Project Grant to Trustees of Dartmouth College to study how the hypoxia morphology of Aspergillus fumigatus (a common fungal pathogen) impacts diagnostic methods for invasive pulmonary aspergillosis (IPA). The key objectives are to 1) investigate how the hypoxia-induced gene HrmA regulates the production of antigenic polysaccharides,...
The University of Massachusetts Medical School (UMMS) was awarded a $840,687 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to conduct research to "Decipher the Role of Bruton's Tyrosine Kinase in the Host Defense Against Aspergillus Fumigatus". The key objectives are to investigate how inhibition of the Bruton's Tyrosine Kinase (BTK) enzyme impacts the immune system's ability to fight invasive Aspergillus fungal infections, particularly in the context of treatments for B-cell cancers. The 5-year project aims to elucidate the molecular mechanisms by which BTK inhibition affects the function of immune cells like neutrophils and tissue-resident macrophages against this opportunistic fungal pathogen. The award was made on August 15, 2025 and is scheduled for completion on July 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $840.7k | 8/15/25 |